Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Celgene's Business Segments
Celgene's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
Celgene does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product Gross0%
- Product100%
- Hematologyand Oncology58.3%
- Product and Service Other0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Gross | $ 5,476 | - |
| Product | $ 4,518 | 100% |
| Hematologyand Oncology | $ 2,634 | 58.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Celgene
Celgene Corp is a biopharmaceutical company that focuses on developing innovative therapeutics for the treatment of cancer and other serious medical conditions. The company was founded in 1986 and is headquartered in Summit, New Jersey, USA. It is widely known for its pioneering work in multiple myeloma, a rare type of cancer that affects plasma cells in the bone marrow.
Celgene's mission is to improve the lives of patients and their families by developing and commercializing therapies that target a wide range of diseases, including cancer, inflammatory conditions, and autoimmune disorders. The company's expertise lies in drug discovery, preclinical research, clinical development, and commercialization.
Celgene has a diverse pipeline of products, which includes multiple myeloma, leukemia, lymphoma, solid tumors, and inflammatory conditions such as psoriasis and Crohn's disease. The company's flagship product is Revlimid (lenalidomide), a first-in-class oral therapy for the treatment of multiple myeloma and myelodysplastic syndromes.
In addition to Revlimid, Celgene also markets Pomalyst (pomalidomide) for multiple myeloma and Dexamethasone for inflammatory conditions. The company's portfolio also includes Otezla (apremilast), a first-in-class oral therapy for the treatment of psoriasis and psoriatic arthritis.
Celgene is committed to advancing the science and understanding of diseases through research collaborations and partnerships with academic institutions, industry organizations, and patient advocacy groups. The company has a strong corporate responsibility program, which includes initiatives to support patient access to its drugs, advance employee health and wellness, and promote environmental sustainability.
Overall, Celgene is a biopharmaceutical company that is dedicated to using innovative science to improve the lives of patients affected by serious medical conditions. The company's focus on drug discovery, clinical development, and commercialization has led to the development of groundbreaking therapies, including several first-in-class medicines that have transformed the treatment landscape for cancer and other diseases.
Celgene's mission is to improve the lives of patients and their families by developing and commercializing therapies that target a wide range of diseases, including cancer, inflammatory conditions, and autoimmune disorders. The company's expertise lies in drug discovery, preclinical research, clinical development, and commercialization.
Celgene has a diverse pipeline of products, which includes multiple myeloma, leukemia, lymphoma, solid tumors, and inflammatory conditions such as psoriasis and Crohn's disease. The company's flagship product is Revlimid (lenalidomide), a first-in-class oral therapy for the treatment of multiple myeloma and myelodysplastic syndromes.
In addition to Revlimid, Celgene also markets Pomalyst (pomalidomide) for multiple myeloma and Dexamethasone for inflammatory conditions. The company's portfolio also includes Otezla (apremilast), a first-in-class oral therapy for the treatment of psoriasis and psoriatic arthritis.
Celgene is committed to advancing the science and understanding of diseases through research collaborations and partnerships with academic institutions, industry organizations, and patient advocacy groups. The company has a strong corporate responsibility program, which includes initiatives to support patient access to its drugs, advance employee health and wellness, and promote environmental sustainability.
Overall, Celgene is a biopharmaceutical company that is dedicated to using innovative science to improve the lives of patients affected by serious medical conditions. The company's focus on drug discovery, clinical development, and commercialization has led to the development of groundbreaking therapies, including several first-in-class medicines that have transformed the treatment landscape for cancer and other diseases.
Celgene Corp, now part of Bristol-Myers Squibb following its acquisition in 2019, has a diverse portfolio encompassing innovative therapies aimed at addressing unmet medical needs primarily in the areas of hematology, oncology, inflammation, immunology, and cellular therapies. The company develops and manufactures a range of pharmaceutical products, which can be broadly categorized into several segments. Below is an extensive description of these segments, products, and services:
1. Hematology and Oncology
Celgene Corp has established itself as a leader in the development of therapies for various hematological malignancies and solid tumors. The product line encompasses several well-known medications:
- REVLIMID (lenalidomide): This oral medication is primarily used for multiple myeloma and certain types of lymphoma, including follicular lymphoma. It works by modulating the immune system, inhibiting tumor growth, and enhancing the apoptosis (programmed cell death) of cancer cells.
- POMALYST (pomalidomide): Another oral agent, POMALYST is indicated for patients with multiple myeloma who have received previous therapies. It acts similarly to REVLIMID, further enhancing immune response and targeting malignant cells.
- IDHIFA (enasidenib): This targeted therapy is designed for patients with acute myeloid leukemia (AML) that has a specific mutation (IDH2). By inhibiting the mutated enzyme, enasidenib aims to reverse the differentiation block in the leukemic cells.
- THALOMID (thalidomide): Originally developed for multiple myeloma, THALOMID has a complex mechanism that includes anti-angiogenesis and modulation of the immune system, aiding in the treatment of several hematologic disorders.
Inflammation and Immunology
In this segment, Celgene develops therapies for autoimmune and inflammatory conditions. Their flagship product includes:
- OTEZLA (apremilast): A breakthrough oral medication for moderate-to-severe plaque psoriasis and psoriatic arthritis, OTEZLA is a phosphodiesterase 4 (PDE4) inhibitor that helps reduce inflammation and improve the quality of life for patients suffering from chronic inflammatory conditions. It works by modulating a pathway in the immune system that leads to lower levels of inflammatory cytokines.
Cellular Therapies
Celgene is pioneering the field of cellular therapies, particularly in personalized medicine through CAR T-cell therapy. Key products in this area include:
- JCAR017: An investigational CAR T-cell therapy that targets CD19 antigen in B-cell malignancies. It represents a novel approach in treating patients with relapsed or refractory forms of certain types of blood cancers.
- bb2121 (ide-cel): This CAR T-cell therapy targets BCMA (B-cell maturation antigen) and is aimed primarily at treating patients with relapsed/refractory multiple myeloma. By genetically modifying T-cells to better identify and attack myeloma cells, bb2121 represents a significant advancement in personalized cancer therapy.
Other Products
Celgene also produces a variety of additional products that serve different health needs:
- VIDAZA (azacitidine): Used as a treatment for myelodysplastic syndromes (MDS) and AML, VIDAZA helps to induce cytogenetic responses and improve overall survival in patients with these conditions.
- EPREX (epoetin alfa): This biological product is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and anemia related to HIV treatment, enhancing red blood cell production.
Overall, Celgenes commitment to developing innovative therapies spans multiple therapeutic areas, particularly focusing on hematology, oncology, and inflammation-related disorders. With a robust pipeline and ongoing clinical trials, the company aims to address various unmet medical needs, enhancing the quality of life for patients battling chronic and life-threatening diseases. After the integration with Bristol-Myers Squibb, the combined resources and expertise promise to further advance its mission in biopharmaceutical development.
1. Hematology and Oncology
Celgene Corp has established itself as a leader in the development of therapies for various hematological malignancies and solid tumors. The product line encompasses several well-known medications:
- REVLIMID (lenalidomide): This oral medication is primarily used for multiple myeloma and certain types of lymphoma, including follicular lymphoma. It works by modulating the immune system, inhibiting tumor growth, and enhancing the apoptosis (programmed cell death) of cancer cells.
- POMALYST (pomalidomide): Another oral agent, POMALYST is indicated for patients with multiple myeloma who have received previous therapies. It acts similarly to REVLIMID, further enhancing immune response and targeting malignant cells.
- IDHIFA (enasidenib): This targeted therapy is designed for patients with acute myeloid leukemia (AML) that has a specific mutation (IDH2). By inhibiting the mutated enzyme, enasidenib aims to reverse the differentiation block in the leukemic cells.
- THALOMID (thalidomide): Originally developed for multiple myeloma, THALOMID has a complex mechanism that includes anti-angiogenesis and modulation of the immune system, aiding in the treatment of several hematologic disorders.
Inflammation and Immunology
In this segment, Celgene develops therapies for autoimmune and inflammatory conditions. Their flagship product includes:
- OTEZLA (apremilast): A breakthrough oral medication for moderate-to-severe plaque psoriasis and psoriatic arthritis, OTEZLA is a phosphodiesterase 4 (PDE4) inhibitor that helps reduce inflammation and improve the quality of life for patients suffering from chronic inflammatory conditions. It works by modulating a pathway in the immune system that leads to lower levels of inflammatory cytokines.
Cellular Therapies
Celgene is pioneering the field of cellular therapies, particularly in personalized medicine through CAR T-cell therapy. Key products in this area include:
- JCAR017: An investigational CAR T-cell therapy that targets CD19 antigen in B-cell malignancies. It represents a novel approach in treating patients with relapsed or refractory forms of certain types of blood cancers.
- bb2121 (ide-cel): This CAR T-cell therapy targets BCMA (B-cell maturation antigen) and is aimed primarily at treating patients with relapsed/refractory multiple myeloma. By genetically modifying T-cells to better identify and attack myeloma cells, bb2121 represents a significant advancement in personalized cancer therapy.
Other Products
Celgene also produces a variety of additional products that serve different health needs:
- VIDAZA (azacitidine): Used as a treatment for myelodysplastic syndromes (MDS) and AML, VIDAZA helps to induce cytogenetic responses and improve overall survival in patients with these conditions.
- EPREX (epoetin alfa): This biological product is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and anemia related to HIV treatment, enhancing red blood cell production.
Overall, Celgenes commitment to developing innovative therapies spans multiple therapeutic areas, particularly focusing on hematology, oncology, and inflammation-related disorders. With a robust pipeline and ongoing clinical trials, the company aims to address various unmet medical needs, enhancing the quality of life for patients battling chronic and life-threatening diseases. After the integration with Bristol-Myers Squibb, the combined resources and expertise promise to further advance its mission in biopharmaceutical development.